m+Medelevator.RU
← Поиск публикаций
American journal of physiology. Heart and circulatory physiology · 2025

The role of α2-adrenergic mechanisms in sympathetic baroreflex control of human blood pressure.

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Spafford Julia E, Limberg Jacqueline K, Harvey Ronée E, Wiggins Chad C, Iannarelli Nathaniel J, Senefeld Jonathon W, Nicholson Wayne T, Curry Timothy B, Joyner Michael J, Shoemaker J Kevin, Baker Sarah E, Klassen Stephen A

Аннотация

This study tested the hypothesis that neural and vascular α2-adrenergic mechanisms contribute to sympathetic baroreflex regulation of human blood pressure. Muscle sympathetic nerve activity (MSNA; peroneal microneurography) was measured, and sympathetic action potentials (APs) were extracted from the filtered MSNA neurogram (continuous wavelet transform) in eight participants (5 females; 28 ± 7 yr) during a baseline (BSL) condition and a dexmedetomidine infusion (DEX; α2-adrenergic receptor agonist; 10-min loading dose at 0.225 µg/kg; maintenance dose: 0.1-0.5 µg/kg/h). Sympathetic AP baroreflex threshold and sensitivity gains were measured (spontaneous method). We quantified the transduction of integrated MSNA to diastolic blood pressure (DBP; signal averaging) and calculated an index of transduction gain as the slope of the relationship between maximum DBP and the number of cardiac cycles to maximum DBP. DEX reset the baroreflex operating point for medium APs to lower firing probabilities (AP cluster 4; BSL: 20 ± 6 to DEX: 6 ± 5%, P < 0.0004), lower DBP (72 ± 9 to 65 ± 10 mmHg, P < 0.0001), and reduced gain (AP cluster 4: -6.5 ± 2.0 to -2.0 ± 0.7%/mmHg, P < 0.0001). DEX reset the AP baroreflex sensitivity operating point to fewer AP clusters/burst (3.4 ± 0.7 to 2.9 ± 0.8 clusters/burst, P = 0.0156) but did not change gain. DEX reduced DBP transduction (cardiac cycle 6: 4.3 ± 3.2 to 3.3 ± 2.0 mmHg, P = 0.0032), increased the time to peak DBP (6 ± 1 to 11 ± 3 cardiac cycles, P = 0.0054), and reduced the DBP transduction gain (0.81 ± 0.72 to 0.36 ± 0.37 mmHg/cardiac cycle, P = 0.0012). These data suggest that neural and vascular α2-adrenergic mechanisms contribute to integrative sympathetic baroreflex regulation of blood pressure in humans.NEW & NOTEWORTHY Intravenous dexmedetomidine infusion (selective α2-adrenergic receptor agonist) 1) reduced the firing probability and strength of baroreflex control over medium-sized sympathetic action potentials in muscle sympathetic nerve activity (MSNA) and 2) attenuated the transduction of MSNA bursts to changes in blood pressure (BP) by reducing the magnitude of BP responses and increasing the time to peak BP. These data suggest that neural and vascular α2-adrenergic mechanisms contribute to sympathetic baroreflex regulation of human BP.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты